Case Studies

Refinement of Residential Turf Risks

During the atrazine re-registration process, EPA identified concerns regarding its use on homeowner lawns. Building upon information found in the public literature, Ms. Rosenheck designed and gained EPA approval to conduct an innovative study to refine children’s nondietary exposure. Data generated from this study allowed for granular formulations of atrazine to remain registered on residential turf. This study design was later used by other registrants.

Helix® Seed Treatment Study

During initial registration of thiamethoxam in 2000, EPA and PMRA indicated the need to characterize worker exposure to Helix® in seed treatment facilities. The study, conducted in Canada, was the largest seed treatment exposure study ever conducted, with 93 full-day replicates. Ms. Rosenheck was a key team member involved with the study conduct that eventually allowed for the registration of Helix.

Diazinon® Lawn & Garden Replacement

Lambda-cyhalothrin was identified as a potential replacement for diazinon® in the homeowner lawn and garden market. Ms. Rosenheck was responsible for providing the exposure and safety evaluations for lambda-cyhalothrin which resulted in Spectracide® Brands registering and selling lambda-cyhalothrin in their Triazicide® consumer product line.

Continued Registration of Brodifacoum in Brazil

To satisfy new legislation regarding the safety of household chemicals under Brazil’s ANVISA, Ms. Rosenheck conducted rodenticide risk assessments for the entire Klerat, Ratak, and Ratex brand portfolio. These assessments were approved, thus allowing sales of this important tool for control of public health pests to continue.

Chlorothalonil® Painter Exposure Study

Ms. Rosenheck was responsible for the design and implementation of this novel exposure monitoring study conducted in California. The purpose of this study was to generate exposure data on professional painters handling latex and water-based paint containing the preservative chlorothalonil®. The data from this study allowed for the continued sales of chlorothalonil® into this market.